The Food and Drug Administration (FDA) authorised the division of Jynneos vaccine doses into fifths to increase the supply, but state and local health authorities are now confronted with new challenges in responding to Monkeypox. Many authorities are unsure of how to immediately adopt the new strategy.
The Jynneos smallpox vaccine, which is being used to stop Monkeypox in the midst of the ongoing outbreak, has a novel route of administration that the FDA approved last week in order to increase the number of doses now available in the United States. Instead than injecting into the muscle like most vaccines are, the procedure entails injecting one-fifth of the typical dose intradermally, between layers of skin.
Local governments face a number of obstacles to implementing the new federal guidance, such as staff members who are not trained to deliver intradermal injections, a lack of specialised needles for these injections, and a lack of financing for additional supplies. Without indicating whether it would proceed with the Jynneos vaccines being divided into fifths, a spokesman for the New York City Department of Health and Mental Hygiene said the department was “reviewing the new guidelines.”